Goldman Sachs
TSVT

Goldman Sachs’s 2seventy bio TSVT Stock Holding History

Goldman Sachs’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,681,675
Closed -$23.1M – 6427
2025
Q1 		$23.1M Buy
4,681,675
+386,774
+9% +$1.23M ﹤0.01% 1897
2024
Q4 		$12.6M Buy
4,294,901
+75,084
+2% +$308K ﹤0.01% 2573
2024
Q3 		$19.9M Buy
4,219,817
+81,972
+2% +$370K ﹤0.01% 2085
2024
Q2 		$15.9M Sell
4,137,845
-83,938
-2% -$378K ﹤0.01% 2064
2024
Q1 		$22.6M Sell
4,221,783
-287,017
-6% -$1.35M ﹤0.01% 1730
2023
Q4 		$19.3M Buy
4,508,800
+3,772,556
+512% +$11.6M ﹤0.01% 1936
2023
Q3 		$2.89M Sell
736,244
-888,008
-55% -$5.82M ﹤0.01% 3469
2023
Q2 		$16.4M Sell
1,624,252
-123,270
-7% -$1.31M ﹤0.01% 2013
2023
Q1 		$17.8M Buy
1,747,522
+696,379
+66% +$7.96M ﹤0.01% 1913
2022
Q4 		$9.85M Sell
1,051,143
-7,076
-0.7% -$99.8K ﹤0.01% 2601
2022
Q3 		$15.4M Buy
1,058,219
+721,910
+215% +$10.7M ﹤0.01% 2093
2022
Q2 		$4.44M Buy
336,309
+219,124
+187% +$2.99M ﹤0.01% 3242
2022
Q1 		$2M Sell
117,185
-391,237
-77% -$6.64M ﹤0.01% 4263
2021
Q4 		$13M Buy
+508,422
New +$15.9M ﹤0.01% 2525

Other funds holding TSVT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Goldman Sachs's TSVT Position: Q2 2025 in Review

Goldman Sachs sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 4,681,675 shares — an estimated $23.1M sold.

Goldman Sachs first reported a position in TSVT in Q4 2021 and held it in 14 quarters. The position peaked at $23.1M in Q1 2025. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

  • Goldman Sachs reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 4,681,675 2seventy bio shares in Q2 2025, an estimated $23.1M.
  • Goldman Sachs first reported a position in 2seventy bio in Q4 2021 and held it in 14 quarters.
  • Goldman Sachs's 2seventy bio position peaked at $23.1M in Q1 2025.
  • 2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.